Looking at the pipelines set out by major manufacturers, The Pharmaceutical Journal highlights some of the most promising and most novel approaches that could be rolled out to patients in the years to come, unpacking how they work and what benefits they could offer
Although final treatment guidelines will depend on future approvals, obesity specialists believe certain patient groups may benefit the most
Join 675+ users modeling their GLP-class levels with the free pharmacokinetic calculator
Semaglutide is a once-weekly GLP-1 injection
Diabetes Metab J 44(6):80218 Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS et al (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
A popular dual agonist, tirzepatide (Mounjaro), activates both GLP-1R and GIPR, producing synergistic effects on insulin secretion, appetite suppression, and weight reduction (Table 1)